Furthermore, specific isoforms of CYP1A2 have shown reduced activity and led to increased BC risk, whereas the − 3860A variant has consistently demonstrated increased metabolic clearance of caffeine and concomitant reduction in BC risk [57, 58]. This evidence concerns the gene CYP1A2 and breast cancer.